A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation
Latest Information Update: 15 Jun 2025
At a glance
- Drugs Ribociclib (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PARFENOPA
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 20 Dec 2024 Planned End Date changed from 30 Jun 2027 to 30 Oct 2027.
- 20 Dec 2024 Planned primary completion date changed from 30 Jun 2027 to 30 Oct 2027.
- 20 Dec 2024 Status changed from not yet recruiting to recruiting.